Executive orders, proclamations, memoranda, determinations, and other instruments — filter by administration, type, and theme.
4 shown · Assistant Secretary for Preparedness and Response
This Executive Order directs the Department of Health and Human Services to fill the Strategic Active Pharmaceutical Ingredients Reserve (SAPIR) with a 6-month supply of APIs for approximately 26 critical drugs, prioritizing domestic manufacturing. It also requires updating the essential medicines list and planning a second repository, while criticizing the prior administration for failing to advance domestic pharmaceutical production.
This executive order directs federal agencies to prioritize domestic procurement of essential medicines, medical countermeasures, and their critical ingredients to reduce dependence on foreign manufacturing. It mandates supply chain vulnerability assessments, streamlines regulatory approvals for domestic producers, and authorizes use of the Defense Production Act to prioritize these materials. The order includes exceptions for public health emergencies and when domestic procurement would increase costs by more than 25 percent.
This executive order establishes a National Influenza Vaccine Task Force co-chaired by Defense and HHS to modernize U.S. influenza vaccine production away from egg-based methods toward faster, scalable cell-based and recombinant technologies. It mandates a 5-year national plan and directs multiple agencies to estimate costs, expand manufacturing capacity, and accelerate development of broadly protective vaccines.
This executive order establishes a government-wide framework to combat antibiotic-resistant bacteria by creating an interagency task force, a presidential advisory council, and mandating specific actions including antibiotic stewardship programs in healthcare facilities, strengthened surveillance systems, promotion of new drug development, and international cooperation. It sets concrete deadlines for a national action plan and regulatory reviews to address what the CDC identified as at least 23,000 annual U.S. deaths from resistant infections.